Lung Cancer

Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Medical Director at Memorial Cancer Institute, Clinical Associate Prof. of Medicine at FL International University provides an update regarding current immunotherapy agents in development for lung cancer.

It’s #GivingTuesday and we're out to win up to $50,000 in the Newman’s Own Foundation $500k Holiday Challenge. Help GRACE so we can continue to help others!

Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a single...

Several weeks ago, at a very crowded plenary session for the European Society of Medical Oncology (ESMO) in Copenhagen, Denmark, results with first...